AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal
AstraZeneca pairs with Insitro on a $1.5B AI collaboration to advance drug targets for MASH and heart conditions.
Stocks · News reference
Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial
Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —Application supported by SAFFRON,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca Entered Strategic Drug Discovery Collaboration, Licensing Agreement With Insitro To Use Advanced AI Systems To Identify Novel Drug Targets, Develop Therapeutics For MASH, Cardiomyopathies
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal
AstraZeneca releases Phase 3 HICKORY trial data for efzimfotase alfa in hypophosphatasia (HPP), showing key secondary improvements.
Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
HUTCHMED has initiated a Phase Ia global clinical trial of HMPL-A830, a first-in-class antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody for treating solid tumors. The first patient was dosed on September 24, 2026. HUTCHMED entered an exclusive development and licensing agreement with GSK on September 3, 2026, granting GSK worldwide rights (excluding Greater China) for development and commercialization.
Reported Sunday, HUTCHMED Doses First Patient In Phase Ia Dose Escalation Of First-In-Class HMPL-A830 To Determine Maximum Tolerated Dose In Advanced Solid Tumors